PanCAN

Our vision is to create a world in which all patients with pancreatic cancer will thrive. 💜

[PanCAN @PanCAN]

Imagine a world where #pancreaticcancer is detected early, where patients are guided to the best care from the moment of diagnosis, and where discoveries move from the lab to saving lives in years, not decades. That is the future PanCAN is building — by bringing together patients, families, researchers and clinicians to transform the future of this disease. 💜

Today at #PanCANPurpleStride, we launch our most ambitious effort yet, the $250 million All Together We Can campaign. Our vision: to make survival the expectation, not the exception, for the tens of thousands of people diagnosed with this disease every year.

Why now? Because this disease remains the deadliest major cancer and the only one with a five-year survival rate below 20%. Because patients and their loved ones deserve more time, more treatment options and more effective screening strategies. Because our community knows that when we’re united in purpose and vision, we can achieve anything — and we’re ready to take on this next chapter.

Learn more about how, over the next five years, the All Together We Can campaign will invest across three strategic pillars — forming a comprehensive approach to accelerate progress and improve survival for pancreatic cancer patients at 🔗 https://t.co/YRDQ5C0KtA.

[PanCAN @PanCAN]

As we celebrate Independence Day, we’re wishing our PanCAN community a safe, joyful and meaningful holiday! 🇺🇸💜

[PanCAN @PanCAN]

When Roberta L. was diagnosed with #pancreaticcancer in 2002, she was given months to live. Twenty-four years later, she's sharing her remarkable story of resilience. 💜

In this episode of PancChat, Roberta joins host @AlisynCamerota to discuss her stage III diagnosis, the role of clinical trials, the lifestyle changes she embraced and how she navigates survivor's guilt. She also shares why she's never made a bucket list — and why she skydives every April instead.

Listen to the latest episode at 🔗 https://t.co/zIzFgM1xUz.

PancChat is a collaboration between @LetsWinPC and PanCAN, sponsored by @RevMedicines.

[PanCAN @PanCAN]

Today, we remember Michael Landon on the anniversary of his passing from #pancreaticcancer. 💜

A beloved actor, writer, director and producer, Michael captured the hearts of millions through iconic roles in Bonanza, Little House on the Prairie and Highway to Heaven. In 1991, he became one of the first public figures to speak openly about his pancreatic cancer diagnosis, helping bring national attention to the disease.

Reflecting on her father's impact, Shawna Landon shared, “I keep my father’s memory alive by living each day to the best of my ability and trying to be of service to others. I instill some of his strong beliefs in my children — to work hard, be a good human being and live each day to the fullest. Never take what you have for granted and whatever you want to do, do it now. There are only so many tomorrows. I miss my dad every day and strive to be the best version of myself to pass on his legacy to my family.”

In 2026, an estimated 67,530 Americans will be diagnosed with pancreatic cancer, and 52,740 are expected to die from the disease. Our vision: to make survival the expectation, not the exception, for people diagnosed with this disease every year. Learn more at 🔗 https://t.co/bAwnfKIRoc.

📷: CBS News, Ed Friendly Productions

[PanCAN @PanCAN]

Today, we proudly announce new appointments to our Board of Directors and Scientific and Medical Advisory Board (SMAB).

Please join us in welcoming Brian Wolpin, MD, MPH to PanCAN's Scientific and Medical Advisory Board.

Dr. Wolpin is a Professor of Medicine at @HarvardMed School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at @DanaFarber Cancer Institute. He serves as Director of the Gastrointestinal Cancer Center and the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, where his work focuses on advancing early detection, biomarker development and precision medicine for #pancreaticcancer. A leader in pancreatic cancer research, Dr. Wolpin also served as principal investigator for @RevMedicines' groundbreaking Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Learn more about PanCAN's SMAB at 🔗 https://t.co/BZnFCdmP6A. Composed of leading cancer scientists, clinicians and healthcare professionals from institutions across the United States who specialize in pancreatic cancer, the SMAB provides scientific and clinical expertise to guide us in planning and implementing our research initiatives, in-depth information and educational services for patients, their families, caregivers and healthcare professionals.

[PanCAN @PanCAN]

Today, we proudly announce new appointments to our Board of Directors and Scientific and Medical Advisory Board (SMAB).

Please join us in welcoming Scott Paulson, MD to PanCAN's Scientific and Medical Advisory Board.

Dr. Paulson is a gastrointestinal medical oncologist at Texas Oncology-Baylor Charles A. Sammons Cancer Center and serves as Medical Director for Clinical Research at @TexasOncology. His work focuses on pancreatic, hepatobiliary and neuroendocrine cancers, with an emphasis on expanding access to clinical trials and advancing treatment options for patients with gastrointestinal malignancies. Active in #pancreaticcancer research for more than a decade, Dr. Paulson is dedicated to increasing access to innovative therapies and improving patient care in community-based settings.

Learn more about PanCAN's SMAB at 🔗 https://t.co/BZnFCdmP6A. Composed of leading cancer scientists, clinicians and healthcare professionals from institutions across the United States who specialize in pancreatic cancer, the SMAB provides scientific and clinical expertise to guide us in planning and implementing our research initiatives, in-depth information and educational services for patients, their families, caregivers and healthcare professionals.

[PanCAN @PanCAN]

As we enter a new era of progress against #pancreaticcancer, we're proud to welcome three exceptional leaders whose expertise will help shape the future of our mission. 💜

Effective today, Peter Bernstein has joined our Board of Directors, and Scott Paulson, MD, and Brian M. Wolpin, MD, MPH, have joined our Scientific and Medical Advisory Board (SMAB).

Their leadership comes at a pivotal moment. Building on decades of research and advocacy, we're seeing unprecedented momentum in pancreatic cancer research — and through our All Together We Can campaign, we're working to accelerate breakthroughs, expand patient services and move closer to the survival rates patients deserve.

PanCAN President and CEO, @JulieFleshman, shares, "We are proud to welcome these new members to PanCAN. They are joining us at an incredibly exciting time as we are finally at a turning point and poised to reap the benefits of decades of investment, advocacy and research into this challenging disease. Their expertise and commitment are critical as we enter this new era in treatments and strengthen our ability to change the trajectory of pancreatic cancer."

Please join us in welcoming Peter, Dr. Paulson and Dr. Wolpin. Read more at 🔗 https://t.co/Aahb61ChVA.

[PanCAN @PanCAN]

Today, we proudly announce new appointments to our Board of Directors and Scientific and Medical Advisory Board (SMAB).

Please join us in welcoming Peter Bernstein to PanCAN's Board of Directors.

Peter is a fourth-generation principal at Alexander Wolf & Son, where he oversees estimating and sales and has led more than $100 million in construction projects across multiple sectors. He holds an MBA from New York University Stern School of Business and a B.S. in Civil Engineering from Cornell University. Peter is also an active nonprofit leader, serving organizations including JCC Manhattan, Park Avenue Synagogue, Belev Echad and UJA committees, and previously served as Co-Chair of the New Leadership Division of Israel Bonds.

Following the loss of his mother to #pancreaticcancer in 2020, Peter has been a dedicated advocate for PanCAN's mission. He has co-captained Team Alexander Wolf & Son for #PanCANPurpleStride New York City and supported a PanCAN research grant focused on precision medicine and early detection.

Learn more about PanCAN's Board of Directors at 🔗 https://t.co/cbm2hOA6fn. Each member has been personally touched by pancreatic cancer and is committed to accelerating progress for everyone affected by this disease.

[PanCAN @PanCAN]

You showed up with hope, determination and compassion at #PanCANPurpleStride — and proved patients can count on you. Every step taken and every dollar raised helps fuel breakthrough research and expand our PanCAN Patient Services program — efforts that are changing what’s possible for patients today and tomorrow. 👟💜

Together, our PurpleStride community has already raised $15.6 million nationwide, an incredible achievement that reflects the strength of this movement. And with fundraising ending tomorrow, we’re so close to reaching our goal.

How close? If every participant raised just $26 we would hit our $17 million goal and invest even more into breakthroughs that can save lives. There’s still time to make an impact before fundraising closes tomorrow. Visit 🔗 https://t.co/cqvqu4a0Iv to make a difference today!

[PanCAN @PanCAN]

In the latest episode of PancChat, host @AlisynCamerota sits down with pancreatic neuroendocrine tumor (PNET) survivor and #PanCANvolunteer, Randi E. to discuss what survivorship can look like more than a decade after diagnosis.

Tune in to PancChat wherever you listen to podcasts, including YouTube 🔗 https://t.co/zIzFgM1xUz

The PancChat Podcast is a collaboration between PanCAN and @LetsWinPC. 💜

[PanCAN @PanCAN]

In this month's Research Spotlight, Dr. @ABerkenblit shares, "I will always remember the 2026 American Society of Clinical Oncology (@ASCO) Annual Meeting as the moment the tide turned in the treatment of pancreatic cancer. I had the honor of attending this conference in late May through early June, and my PanCAN colleagues and I rose to our feet for a standing ovation alongside an estimated 18,000 oncology healthcare professionals, advocates and other attendees to applaud the stunning overall survival data from the RASolute-302 phase 3 clinical trial.

The RASolute-302 trial tested @RevMedicines’ #daraxonrasib, a once-daily pill that blocks RAS, compared to standard intravenous chemotherapy in patients with previously treated metastatic pancreatic cancer.

An important topic discussed at the ASCO meeting was management of the side effects that result from daraxonrasib. Many people have seen media coverage of the facial rash experienced by former Senator Ben Sasse while receiving daraxonrasib in a clinical trial for pancreatic cancer. For most people, the rash with daraxonrasib is not severe, especially with proactive measures to prevent and manage the rash including sun protection, antibiotics and steroid creams. Similarly, there was discussion around stomatitis, or mouth sores, which was the second most common side effect experienced by patients treated with daraxonrasib. Oral hygiene, mouthwashes and dietary changes can be implemented to help mitigate this side effect.

While the results from the RASolute-302 clinical trial are unprecedented for the treatment of pancreatic cancer, we know that this is not enough."

Read more at 🔗 https://t.co/aqcsJjua7U.

[PanCAN @PanCAN]

Two months ago, we took steps to end pancreatic cancer at #PanCANPurpleStride! If you had to describe your day in just one emoji, which would you choose?

💜👟🎗️🥹🫶👏🫂✨

There's still time to make an impact. You have until June 30 to donate to a strider, team or event! Visit https://t.co/cqvqu4a0Iv to support patients and families affected by pancreatic cancer today.

[Anna Berkenblit, MD, MMSc @aberkenblit]

In this month's @PanCAN Research Spotlight, I look back on the progress shared at this year's @ASCO Annual Meeting and what it means for patients moving forward. #ASCO26

🔗 https://t.co/yz1HYoXMRR

[PanCAN @PanCAN]

We stand with @OVACInfo and organizations across the #cancer community in calling on the Administration to protect progress against cancer. 💜

[OVAC @OVACInfo]

OVAC is raising concerns about an OMB proposal that could undermine expert-driven cancer research and disrupt progress for patients and families. Federal science must stay grounded in merit.

Read the full statement on our site: https://t.co/13hL9IXcAL

[PanCAN @PanCAN]

Join PanCAN for our virtual event, KRAS and Pancreatic Cancer: Entering a New Era of Treatment, where we'll discuss the current moment in KRAS research and what the newest discoveries may mean for patients now and in the future. 🧬

RSVP now at 🔗 https://t.co/R3BDPLe2qS.

[PanCAN Boston @PanCANBoston]

Join @PanCAN on Thursday, June 25, for a webinar focused on KRAS and pancreatic cancer 🧬 RSVP today ➡️ https://t.co/t8RpL69rfP

[Verastem Oncology @VerastemOncolog]

Pancreatic cancer remains one of the most difficult cancers to treat, with limited therapeutic advances and a five-year survival rate of approximately 3% for metastatic disease. More than 90% of pancreatic tumors harbor KRAS mutations with KRAS-driven signaling and FAK-mediated resistance pathways a central driver of disease progression.

Today, we announced positive updated results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer. These findings provide encouraging evidence that combined RAF/MEK and FAK inhibition alongside standard-of-care chemotherapy may help address key mechanisms of resistance in pancreatic cancer.

We are especially grateful to the patients, families, and investigators who made this research possible, and to the @PanCAN who selected Verastem Oncology in 2022 to receive the inaugural PanCAN Therapeutic Accelerator Award, which helped support the evaluation of this novel treatment approach and fostered important collaboration between Verastem and the pancreatic cancer research community.

Read more here: https://t.co/IqAYyfPOKO

#PancreaticCancer #PDAC #KRAS #OncologyResearch #CancerResearch #ClinicalTrials #RASPathway #PanCAN $VSTM

[UNC Lineberger @UNC_Lineberger]

Timely webinar on 6/25 to discuss the current moment in KRAS research – and what the newest discoveries may mean for patients now and in the future. Plus, Lineberger member Kirsten Bryant, PhD, is one of the panelists!

RSVP today: https://t.co/i5YWFTsTOP

[PanCAN @PanCAN]

💜

[Rogel and Blondy Center for Pancreatic Cancer @UMICHpancreas]

Big news in pancreatic cancer! The Rogel and Blondy Center for Pancreatic Cancer at University of Michigan is proud to announce we have obtained access to daraxonrasib through the expanded access program.

[PanCAN @PanCAN]

Randi E. was diagnosed with a pancreatic neuroendocrine tumor (PNET) in her 30s. Although she underwent a total pancreatectomy, she continues treatment to help keep the tumor under control. In the years since her diagnosis, Randi has become insulin-dependent, lost her mother to #pancreaticcancer and built a meaningful life as a health equity advocate and dedicated #PanCANvolunteer with PanCAN’s Survivor Council and Health Equity Committee.

In this episode of PancChat, host @AlisynCamerota sits down with Randi to discuss what survivorship can look like more than a decade after diagnosis. Randi shares the realities of ongoing care, including monthly injections, annual scans, diabetes management and the emotional complexities of navigating life as both a patient and caregiver. Together, they explore the importance of sharing a diagnosis with a broader support network, the role health equity plays in access to care and treatment and why reaching the five-year mark is often not the end of the journey.

Tune in to PanChat wherever you listen to podcasts, including YouTube 🔗 https://t.co/zIzFgM1xUz

The PancChat Podcast is a collaboration between PanCAN and @LetsWinPC. 💜